Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
Baboudjian M, Roubaud G, Fromont G, Gauthé M, Beauval JB, Barret E, Brureau L, Créhange G, Dariane C, Fiard G, Mathieu R, Ruffion A, Rouprêt M, Renard-Penna R, Sargos P, Ploussard G; Prostate Cancer Committee of the French Association of Urology. Baboudjian M, et al. Among authors: crehange g. World J Urol. 2023 Aug;41(8):2033-2041. doi: 10.1007/s00345-022-04239-1. Epub 2022 Dec 9. World J Urol. 2023. PMID: 36484817 Review.
Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU).
Sargos P, Guerif S, Latorzeff I, Hennequin C, Pommier P, Lagrange JL, Créhange G, Chapet O, de Crevoisier R, Azria D, Supiot S, Habibian M, Soulié M, Richaud P. Sargos P, et al. Among authors: crehange g. Cancer Treat Rev. 2015 Dec;41(10):814-20. doi: 10.1016/j.ctrv.2015.10.005. Epub 2015 Oct 23. Cancer Treat Rev. 2015. PMID: 26508669 Review.
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N'Guyen TD, Suchaud JP, Créhange G, Barbier N, Habibian M, Ferlay C, Fourneret P, Ruffion A, Dussart S. Carrie C, et al. Among authors: crehange g. Lancet Oncol. 2016 Jun;17(6):747-756. doi: 10.1016/S1470-2045(16)00111-X. Epub 2016 May 6. Lancet Oncol. 2016. PMID: 27160475 Clinical Trial.
[Hypofractionnated radiotherapy for elderly patients with prostate cancer].
Sargos P, Créhange G, Hennequin C, Latorzeff I, de Crevoisier R, Roubaud G, Supiot S. Sargos P, et al. Among authors: crehange g. Cancer Radiother. 2018 Oct;22(6-7):631-634. doi: 10.1016/j.canrad.2018.07.124. Epub 2018 Aug 23. Cancer Radiother. 2018. PMID: 30145092 Review. French.
Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07).
Vaugier L, Palpacuer C, Rio E, Goineau A, Pasquier D, Buthaud X, De Laroche G, Beckendorf V, Sargos P, Créhange G, Pommier P, Loos G, Hasbini A, Latorzeff I, Silva M, Denis F, Lagrange JL, Campion L, Supiot S. Vaugier L, et al. Among authors: crehange g. Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1061-1067. doi: 10.1016/j.ijrobp.2018.12.020. Epub 2018 Dec 14. Int J Radiat Oncol Biol Phys. 2019. PMID: 30557672 Free article. Clinical Trial.
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, Supiot S, Belkacemi Y, Peiffert D, Allouache N, Dubray BM, Servagi-Vernat S, Suchaud JP, Crehange G, Guerif S, Brihoum M, Barbier N, Graff-Cailleaud P, Ruffion A, Dussart S, Ferlay C, Chabaud S. Carrie C, et al. Among authors: crehange g. Lancet Oncol. 2019 Dec;20(12):1740-1749. doi: 10.1016/S1470-2045(19)30486-3. Epub 2019 Oct 16. Lancet Oncol. 2019. PMID: 31629656 Clinical Trial.
[Indications and outlooks of radiohormonal therapy of high-risk prostate cancers].
Latorzeff I, Sargos P, Créhange G, Belkacémi Y, Azria D, Hasbini A, Dubergé T, Toledano A, Graff-Cailleaud P, Chapet O, Hennequin C, de Crevoisier R, Supiot S, Pasquier D. Latorzeff I, et al. Among authors: crehange g. Cancer Radiother. 2020 Apr;24(2):143-152. doi: 10.1016/j.canrad.2019.06.018. Epub 2020 Feb 11. Cancer Radiother. 2020. PMID: 32057646 Review. French.
Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group.
Belkacemi Y, Latorzeff I, Hasbini A, Coraggio G, Pasquier D, Toledano A, Hennequin C, Bossi A, Chapet O, Crehange G, Guerif S, Duberge T, Allouache N, Clavere P, Gross E, Supiot S, Azria D, Bolla M, Sargos P. Belkacemi Y, et al. Among authors: crehange g. Cancer Radiother. 2020 Dec;24(8):892-897. doi: 10.1016/j.canrad.2020.03.014. Epub 2020 Nov 2. Cancer Radiother. 2020. PMID: 33144063 Review.
225 results